Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer Clinical Trial

Official title:

Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01355484
• Other study ID #: G300504
• Secondary ID: POWER1
• Status: Completed
• Phase: Phase 3
• First received: May 12, 2011
• Last updated: February 4, 2016
• Start date: July 2011
• Est. completion date: June 2014

Study information

• Verified date: February 2016
• Source: GTx
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUkraine: Ministry of HealthPoland: Ethics CommitteeRussia: Ministry of Health of the Russian FederationHungary: Research Ethics Medical CommitteeChile: Ministry of HealthPeru: Ministry of HealthArgentina: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called "lean body mass".

Description:

This is a randomized, double-blind, placebo controlled, multicenter, multinational efficacy and safety study in subjects with non small cell lung cancer (NSCLC). Subjects will be evenly randomized to placebo or GTx-024 prior to initiation of first line chemotherapy. The primary efficacy analysis will be based on total lean body mass and physical function.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 321
• Est. completion date: June 2014
• Est. primary completion date: May 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• give voluntary, signed informed consent in accordance with institutional policies

• be non-obese as defined as body mass index (BMI)< or = to 32 and weight <300 pounds (<136kg)

• have been diagnosed with Stage III or IV NSCLC

• be prior to first line chemotherapy

• planned first line chemotherapy regimen is platinum plus paclitaxel only or platinum plus docetaxel only

• if surgery is part of the cancer treatment, screening for this study should be conducted at least 4 weeks (28 days) after surgery

• life expectancy of >6 months

• ECOG score <or=1

• Serum creatinine <or=2.0 mg/dL

• MALES - age >or= 30 years

• FEMALES - age >or=30 years and clinically confirmed as postmenopausal.Subjects must have undergone the onset of spontaneous or surgical menopause prior to the start of this study. Spontaneous menopause is defined as the natural cessation of ovarian function as indicated by being amenorrheic for at least 12 months. If the subject has been amenorrheic for >or=6 months but <12 months they must have a serum FSH concentration of >or=50 mIU/mL and an estradiol concentration of <or=25 pg/mL. Surgical menopause is defined as bilateral oophorectomy.

• MALES - subjects must agree to use a double barrier method of contraception during the study and for 3 months after study completion. This may include the following: condom + spermicide or condom + oral hormonal contraception

• MALES - have a serum PSA of <or=4.0 ng/mL or a negative prostate biopsy (no prostate cancer)within 6 months of evaluation

Exclusion Criteria:

• Have, in the judgment of the investigator, a clinically significant concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol

• Have ALT/SGOT or AST/SGPT above 1.5 times the upper limit of normal (ULN) without evidence of liver metastases and above 5 times the ULN in subjects with evidence of liver metastases

• Have alkaline phosphatase greater than 3 times ULN and/or total bilirubin levels above 2 mg/dL at baseline

• Have biologic agents or kinase inhibitors as part of their first line chemotherapy regimen including, but not limited to bevacizumab (Avastin), gefitinib (Nexavar) and erlotinib (Tarceva)

• Cardiovascular: uncontrolled hypertension, congestive heart failure or angina

• Pulmonary: Stage 4 chronic obstructive pulmonary disease (COPD)

• positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen), unless subject was diagnosed > 10 years prior to enrollment and no evidence of active liver disease

• positive screen for anti-HCV (Hepatitis C Antibody),hepatitis A antibody IgM, or HIV

• currently taking testosterone, oxandrolone (Oxandrin), testosterone-like agents (such as dehydroepiandrosterone (DHEA), androstenedione, and other androgenic compounds, including herbals), or antiandrogens; previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the medical monitor for this study to determine appropriate washout period)

• currently taking megestrol acetate (Megace), dronabinol (Marinol), medical marijuana (medical cannabis) or any prescription medication intended to increase appetite or treat unintentional weight loss

• have a baseline stair climb time >or=30 seconds (mean of two stair climbs)

• Have active cancer, other than NSCLC, or non-melanoma carcinoma of the skin, within the previous two years

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cachexia
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Muscle Wasting
• Muscular Atrophy
• Non Small Cell Lung Cancer

Intervention

Drug:
• GTx-024
subjects will be randomized to receive GTx-024 for the full duration of the trial.
• placebo
subject will receive placebo for the duration of the trial

Locations

Country	Name	City	State
United States	GTx Investigative Site	Ashland	Kentucky
United States	GTx Investigative Site	Aventura	Florida
United States	GTx Investigative Site	Birmingham	Alabama
United States	GTx Investigative Site	Burlington	North Carolina
United States	GTx Investigative Site	Canfield	Ohio
United States	Gabrail Cancer Center	Canton	Ohio
United States	GTx Investigative Site	Concord	Massachusetts
United States	GTx Investigative Site	Decatur	Illinois
United States	GTx Investigative Site	Flat Rock	North Carolina
United States	GTx Investigative Site	Great Falls	Montana
United States	GTx Investigative Site	Indianapolis	Indiana
United States	GTx Investigative Site	Lancaster	Pennsylvania
United States	GTx Investigative Site	Long Beach	California
United States	GTx Investigative Site	Miami	Florida
United States	GTx Investigative Site	Orange City	Florida
United States	GTx Investigative Site	Peoria	Illinois
United States	GTx Investigative Site	Portland	Oregon
United States	GTx Investigative Site	Rochester	New York
United States	GTx Investigative Site	Round Rock	Texas
United States	GTx Investigative Site	Sandusky	Ohio
United States	GTx Investigative Site	Skokie	Illinois
United States	GTx Investigative Site	Spartanburg	South Carolina
United States	GTx Investigative Site	St Clair Shores	Michigan
United States	GTx Investigative Site	Tampa	Florida
United States	GTx Investigative Site	Tupelo	Mississippi
United States	GTx Investigative Site	Wilmington	North Carolina
United States	GTx Investigative Site	Winston Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
GTx

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Physical Function	Measure is the percentage of subjects at day 84 with stair climb power change >=10% from their baseline value.	Day 84	No
Primary	Lean Body Mass	Measure is the percentage of subjects at day 84 with lean body mass change >=0% from their baseline value.	Day 84	No